Prof. Peer Dan

  
Affiliation:The George S.Wise faculty of life sciences
Tel:  (972)-3-6407925
(972)-3-6407925
 
Fax: (972)-3-6407925
 
Email: peer@tau.ac.il
 
Personal Website:

 
Postal Address:The George S.Wise faculty of life sciences
Tel Aviv University
Tel Aviv 69978

Research Interest

Selective targeting and reprogramming of cells using fully degradable nanomedicines
In the laboratory of Nanomedicine we are studying how to manipulate cells functions in order to generate novel therapeutic strategies to treat inflammatory diseases and cancers. We operate in a two-arm approach. In the first, we design, fabricate, develop and characterize novel nanocarriers for selective systemic targeting to variety of cell types involved in inflammatory diseases and different types of cancers. In the second, we utilize our technologies for drug discovery, and personalized medicine approach. In both arms, we are combining multidisciplinary approaches including immunology, cell and molecular biology, genetics, protein engineering, material sciences, nanotechnology and computational techniques to develop innovative therapeutics to target specific cells within the immune system and special epithelial cells. Our ultimate goal is to translate some of our findings into clinical settings.

We are particularly interested in:

  1. Identifying key genes responsible for multipotent hematopoietic stem cells self-renewal properties.
  2. Studying the role of cell cycle regulators in proliferation, migration, and cytokine production in lymphocytes, macrophages and dendritic cells during inflammatory bowel diseases.
  3. Developing and studying novel approaches to target cancer stem cells.
  4. Harnessing siRNAs and miRNAs as novel tools for drug discovery and for therapeutic applications.
  5. Investigating novel approaches to treat blood cancers such as mantle cell lymphoma and acute myeloid leukemia.
  6. Manipulation of hair follicle stem cells to control hair growth, and skin cancers.

 

Selective targeting of siRNAs (red) into activated lymphocytes (green) using fusion protein that target conformation-selective integrin LFA-1. Naive cells (not stained) do not uptake siRNAs.

Selected Publications


  • Peer D (2010). Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: an overview of RNAi delivery to leukocytes. Journal of Controlled Release.
  • Dearling JJ, Voss S, Dunning P, Park EJ, Fahey F, Treves T Solapino S., Shimaoka M, Packard AB, Peer D (2010). Detection of Intestinal Inflammation by PET Imaging Using a 64Cu-Labeled Anti-7 Integrin Antibody. Inflammatory Bowel Disease. In press.
  • Rivkin I, Cohen K, Koffler J, Malichov D, Peer D and Margalit R (2010). Paclitaxel-clusters coated with hyaluronan as selective tumor-targeting nanovectors. Biomaterials 31, 7106-7114
  • Kedmi R*, Ben-Arie N*, and Peer D (2010). The systemic toxicity of positively charged lipid-nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31, 6867-6875.
  • Weinstein S., and Peer D (2010). RNAi Nanomedicines: challenges and opportunities within the immune system. Nanotechnology, 21(23), 232001, 1-13.
  • Kim S-S*, Peer D* , Kumar P *, Wu H, Asthana D, Habiro K, Yang Y-G, Manjunath N, Shimaoka M, Shankar P (2010). RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in humanized mice. Molecular Therapy, 18, 370-376.
  • Kedmi R., and Peer D (2009). RNAi nanoparticles in the service of personalized medicine. Nanomedicine, 4(8), 853-855.
  • Peer D. (2009). Nanocarriers delivering RNAi to cancer cells: from challenge to cautious optimism. Therapy. 6, (3), 293-296.
  • Peer D. and Shimaoka M (2009) Systemic siRNA delivery to leukocyte-implicated diseases. Cell Cycle 8, 853-9.
  • Peer D, Park EJ, Morishita Y, Carman CV, and Shimaoka M (2008). Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammation Target. Science. 319, 627-630.
  • Peer D, Zhu P, Carman CV, Lieberman J and Shimaoka M. (2007). Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function- associated antigen-1. Proc. Natl. Acad. Sci. USA, 104, 4095-4100.
  • Peer D, Karp JM, Hong S, Farokhzad O, Margalit R, and Langer R (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology. 2,751-760.